Overview

Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

Status:
Active, not recruiting

Trial end date:
2022-02-26

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label extension (OLE) study designed to assess the extended long-term safety of evolocumab in subjects who have completed the FOURIER trial (Study 20110118). Approximately 1600 subjects will be enrolled in this study. This study will continue for 260 weeks (approximately 5 years).

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Evolocumab